FROM 11/13: FWIW

• ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis
• ZORYVE, a next-generation topical phosphodiesterase-4 (PDE4) inhibitor, recognized for redefining topical treatment drug delivery for immune-mediated skin diseases and for its proprietary formulation

WESTLAKE VILLAGE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.(NASDAQ: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis' ZORYVE ^®(roflumilast) cream 0.15% has received Glamour's2024 Health and Wellness awardfor Best Eczema Product. The Best Beauty Innovators category acknowledges breakthrough innovations from the past year.

"This prestigious award from Glamouris a testament to the exceptional work of our research and development and technical operations teams to formulate ZORYVE, a highly selective and potent PDE4 inhibitor. As a result, ZORYVE is an effective, well tolerated, moisturizing topical that can be applied anywhere on the body for any duration. ZORYVE delivers its active ingredient in a formulation that is free of any excipients, irritants, or sensitizers that could further compromise a patient's skin barrier, which is critical for chronic skin conditions like eczema," said Frank Watanabe, president and CEO of Arcuti